Salud
FDA approves Syndax blood cancer drug
The US Food and Drug Administration has approved Syndax Pharmaceuticals’ drug for the treatment of adult and paediatric patients with a type of blood cancer.
CDC confirms first human case of bird flu in Oregon
The US Centers for Disease Control and Prevention (CDC) has confirmed a highly pathogenic form of avian influenza in a person in Oregon. The infected
Cigna says it is not seeking a deal with rival Humana
Cigna Group said it is not seeking a merger with rival health insurer Humana. Days after Donald Trump’s re-election as US president, investors harboured hopes
AstraZeneca raises its 2024 outlook
Drugmaker AstraZeneca raised its annual sales and profit forecast for the second time this year, helped by strong demand for its cancer and rare disease
Bayer shares fall to a 20-year low
Bayer said weak agricultural markets mean its profits are likely to fall further next year, triggering a sharp drop in the German company’s shares and
FDA approves Johnson & Johnson device for heart disease
The US FDA has approved J&J’s device for a type of condition that causes abnormal heart rhythms, the company said. The device, Varipulse, is a
Moderna reports unexpected profit due to higher sales of COVID vaccine
Moderna on Thursday reported an unexpected third-quarter profit, driven by cost cuts and better-than-expected sales of its COVID-19 vaccine, even though revenue from its new
Australia approves $5.8bn Chemist Warehouse-Sigma Healthcare deal
Australia’s competition regulator on Thursday approved the reverse takeover of Sigma Healthcare by private pharmacy chain Chemist Warehouse, paving the way for the A$8.8 billion
Novo Nordisk is aware of 10 deaths from counterfeit weight loss products
Novo Nordisk on Wednesday the company said it was aware of 10 deaths and 100 hospitalisations as a result of people taking combination copies of
Siemens Healthineers hit full-year revenue and profit forecasts, shares up 8%
Siemens Healthineers on Wednesday the company met forecasts for full-year revenue and profit growth as strength in its imaging segment and U.S. cancer treatment unit